{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:02:27Z","timestamp":1792270947979,"version":"4.4.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.lanepe.2021.100222","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T05:24:56Z","timestamp":1631078696000},"page":"100222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding"],"prefix":"10.1016","volume":"10","author":[{"given":"Wai Hoong","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie H.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen Yi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-8095","authenticated-orcid":false,"given":"Alvina G.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2021.100222_bib0001","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.cgh.2019.07.060","article-title":"Contemporary epidemiology of chronic liver disease and cirrhosis","volume":"18","author":"Moon","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2021.100222_bib0003","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0004","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cgh.2011.12.039","article-title":"Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population","volume":"10","author":"Stepanova","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142937","article-title":"Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study)","volume":"10","author":"K\u00e4r\u00e4j\u00e4m\u00e4ki","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2021.100222_bib0007","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0008","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000442877","article-title":"The complex role of anticoagulation in cirrhosis: an updated review of where we are and where we are going","volume":"93","author":"Khoury","year":"2016","journal-title":"Digestion"},{"key":"10.1016\/j.lanepe.2021.100222_bib0009","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.3390\/ijms17101714","article-title":"The importance of patient-specific factors for hepatic drug response and toxicity","volume":"17","author":"Lauschke","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.lanepe.2021.100222_bib0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2021.100222_bib0011","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2021.100222_bib0012","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2021.100222_bib0013","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2021.100222_bib0014","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1161\/CIRCOUTCOMES.113.000817","article-title":"Stratifying the risks of oral anticoagulation in patients with liver disease","volume":"7","author":"Efird","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.lanepe.2021.100222_bib0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lanepe.2021.100222_bib0016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","article-title":"Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct F actor X a inhibitor","volume":"76","author":"Kubitza","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0017","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep4.1513","article-title":"Direct oral anticoagulants in patients with atrial fibrillation and advanced liver disease: an exploratory meta-analysis","volume":"4","author":"Violi","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.lanepe.2021.100222_bib0018","unstructured":"Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. Accessed 24 May 2021. https:\/\/www.ema.europa.eu\/en\/evaluation-pharmacokinetics-medicinal-products-patients-impaired-hepatic-function."},{"key":"10.1016\/j.lanepe.2021.100222_bib0019","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/hep4.1254","article-title":"Use of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease","volume":"2","author":"Schwarzkopf","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.lanepe.2021.100222_bib0020","series-title":"Seminars in thrombosis and hemostasis","first-page":"184","article-title":"Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity","author":"Niitsu","year":"2005"},{"key":"10.1016\/j.lanepe.2021.100222_bib0021","unstructured":"NICE. Clopidogrel. Accessed 24 May 2021. https:\/\/cks.nice.org.uk\/topics\/antiplatelet-treatment\/prescribing-information\/clopidogrel\/."},{"key":"10.1016\/j.lanepe.2021.100222_bib0022","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/S0140-6736(05)67660-X","article-title":"Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2021.100222_bib0023","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2021.100222_bib0024","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u20229 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0025","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/jamia\/ocz105","article-title":"UK phenomics platform for developing and validating electronic health record phenotypes: CALIBER","volume":"26","author":"Denaxas","year":"2019","journal-title":"J Am Med Informatics Assoc"},{"key":"10.1016\/j.lanepe.2021.100222_bib0026","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.lanepe.2021.100222_bib0027","unstructured":"Banerjee A, Benedetto V, Gichuru P, et\u00a0al. Adherence and persistence to direct oral anticoagulants in atrial fibrillation\u00a0: a population- based study. 2019;: 1\u20138."},{"key":"10.1016\/j.lanepe.2021.100222_bib0028","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lanepe.2021.100222_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0174426","article-title":"Computation of adherence to medication and visualization of medication histories in R with AdhereR: towards transparent and reproducible use of electronic healthcare data","volume":"12","author":"Dima","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lanepe.2021.100222_bib0030","unstructured":"West Suffolk Clinical Commissioning Group. Dabigatran,rivaroxabanand apixaban, the new oral anticoagulants (NOACS), forthe prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Accessed 24 May 2021. https:\/\/www.westsuffolkccg.nhs."},{"key":"10.1016\/j.lanepe.2021.100222_bib0031","unstructured":"Buckinghamshire Clinical Commissioning Group. Apixaban, dabigatran, edoxaban and rivaroxaban for non-valvular atrial fibrillation prescribing guidelines. Accessed 24 May 2021. http:\/\/www.bucksformulary.nhs.uk\/docs\/Guideline_313FM.pdf."},{"key":"10.1016\/j.lanepe.2021.100222_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-68304-8","article-title":"Oral anticoagulants and risk of acute liver injury in patients with nonvalvular atrial fibrillation: a propensity-weighted nationwide cohort study","volume":"10","author":"Maura","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.lanepe.2021.100222_bib0033","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/heartjnl-2013-305288","article-title":"Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis","volume":"100","author":"Caldeira","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.lanepe.2021.100222_bib0034","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jacc.2018.01.009","article-title":"Non\u2013vitamin K antagonist oral anticoagulants and risk of serious liver injury","volume":"71","author":"Douros","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lanepe.2021.100222_bib0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2021.100222_bib0036","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.lanepe.2021.100222_bib0037","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cger.2012.01.008","article-title":"Medication adherence to multidrug regimens","volume":"28","author":"Marcum","year":"2012","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.lanepe.2021.100222_bib0038","unstructured":"NICE. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. Accessed 24 May 2021. https:\/\/www.nice.org.uk\/guidance\/cg76\/chapter\/introduction."},{"key":"10.1016\/j.lanepe.2021.100222_bib0039","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.lanepe.2021.100222_bib0040","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.lanepe.2021.100222_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.115.003074","article-title":"Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.lanepe.2021.100222_bib0042","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ahj.2014.03.023","article-title":"Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the Veterans Health Administration","volume":"167","author":"Shore","year":"2014","journal-title":"Am Heart J"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622100199X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266677622100199X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:46:40Z","timestamp":1763009200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266677622100199X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":42,"alternative-id":["S266677622100199X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100222","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100226","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100222"}}